We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Big Pharma Using Corporate Tax Savings to Lower Drug Costs?
Read MoreHide Full Article
With the passing of the new tax bill, the corporate tax rate has come down from 35% to 21% which is likely to boosts profit margins. Moreover, the cash repatriation window allowed in the bill will help companies to bring in cash stashed in foreign locations at a one-time tax rate of 10%, leaving these companies with extra spending power.
Most big pharma companies discussed their plans to use the extra cash they save from the new tax bill at their fourth-quarter conference calls. The extra cash will mostly be invested in capital expenditures, products/pipeline, in-licensing or acquisition deals or rewarding shareholders through higher dividends and share buybacks. However, the majority of companies did not mention any effort regarding lowering of prescription drug costs.
Last week, Senator Tina Smith in letters to five big pharma companies, expressed concern about how big pharma companies plan to used billions of dollars they will save from the tax cut offered under the tax bill passed in December 2017. She is concerned about the fact that the companies are favoring investors instead of using the savings to bring down prescription drug costs. Major life-saving drugs which are protected by patents are steeply priced. Thus, making these drugs affordable will help consumers, as it will lower their medical costs.
The Senator has sent letters to CEOs of Pfizer Inc. (PFE - Free Report) , Merck & Co., Inc. (MRK - Free Report) , Johnson & Johnson (JNJ - Free Report) , AbbVie Inc. (ABBV - Free Report) and Abbott Laboratories (ABT - Free Report) to provide the details of how they intend to utilize major savings from the tax overhaul.
The prices of major prescription drugs have skyrocketed over the past years, pinching hard U.S. citizens as their medical bills have soared. Moreover, the government also has to pay higher costs for the drugs that are covered under Medicare. The concern of the senator is thus justified. A move to restrict the use of tax savings for boosting shareholders will be a welcome move for consumers.
Moreover, large players from every other industry have similar plans, which have undercut President Donald Trump’s plans to create jobs and boost wages.
Senator Smith is also working toward making cheaper generic drugs available in the market faster by introducing a new legislation, as reported by KDAL.
Don’t Even Think About Buying Bitcoin Until You Read This
The most popular cryptocurrency skyrocketed last year, giving some investors the chance to bank 20X returns or even more. Those gains, however, came with serious volatility and risk. Bitcoin sank 25% or more 3 times in 2017.
Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
Image: Bigstock
Is Big Pharma Using Corporate Tax Savings to Lower Drug Costs?
With the passing of the new tax bill, the corporate tax rate has come down from 35% to 21% which is likely to boosts profit margins. Moreover, the cash repatriation window allowed in the bill will help companies to bring in cash stashed in foreign locations at a one-time tax rate of 10%, leaving these companies with extra spending power.
Most big pharma companies discussed their plans to use the extra cash they save from the new tax bill at their fourth-quarter conference calls. The extra cash will mostly be invested in capital expenditures, products/pipeline, in-licensing or acquisition deals or rewarding shareholders through higher dividends and share buybacks. However, the majority of companies did not mention any effort regarding lowering of prescription drug costs.
Last week, Senator Tina Smith in letters to five big pharma companies, expressed concern about how big pharma companies plan to used billions of dollars they will save from the tax cut offered under the tax bill passed in December 2017. She is concerned about the fact that the companies are favoring investors instead of using the savings to bring down prescription drug costs. Major life-saving drugs which are protected by patents are steeply priced. Thus, making these drugs affordable will help consumers, as it will lower their medical costs.
The Senator has sent letters to CEOs of Pfizer Inc. (PFE - Free Report) , Merck & Co., Inc. (MRK - Free Report) , Johnson & Johnson (JNJ - Free Report) , AbbVie Inc. (ABBV - Free Report) and Abbott Laboratories (ABT - Free Report) to provide the details of how they intend to utilize major savings from the tax overhaul.
The prices of major prescription drugs have skyrocketed over the past years, pinching hard U.S. citizens as their medical bills have soared. Moreover, the government also has to pay higher costs for the drugs that are covered under Medicare. The concern of the senator is thus justified. A move to restrict the use of tax savings for boosting shareholders will be a welcome move for consumers.
Moreover, large players from every other industry have similar plans, which have undercut President Donald Trump’s plans to create jobs and boost wages.
Senator Smith is also working toward making cheaper generic drugs available in the market faster by introducing a new legislation, as reported by KDAL.
Large Cap Pharmaceuticals Industry 5YR % Return
Large Cap Pharmaceuticals Industry 5YR % Return
Don’t Even Think About Buying Bitcoin Until You Read This
The most popular cryptocurrency skyrocketed last year, giving some investors the chance to bank 20X returns or even more. Those gains, however, came with serious volatility and risk. Bitcoin sank 25% or more 3 times in 2017.
Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 4 crypto-related stocks now >>